HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon Under SEC Probe; Outlook “So Bad It’s Good,” Analyst Says

This article was originally published in The Rose Sheet

Executive Summary

In an Oct. 27 filing with the Securities and Exchange Commission, Avon Products Inc. discloses that it has received a subpoena from the SEC concerning its interactions with analysts.

You may also be interested in...



Coty Makes Offer For Avon, Smelling “Blood in the Water” – Analyst

Coty envisions “an iconic beauty company” to emerge from its proposed acquisition of Avon; however, the direct seller’s management has dismissed the offer as “opportunistic” and not in shareholders’ best interest. Coty is now appealing directly to shareholders, highlighting the firms’ complementary product portfolios and geographical strengths. Meanwhile, Avon seems intent on finding growth and profitability on its own.

Avon Clearing the Decks: Firm Ousts Cramb Amid Ongoing Investigation

Avon announces dismissal of Vice Chairman Charles Cramb in connection with firm’s internal investigation into possible breach of fiduciary duty and alleged violations of the Foreign Corrupt Practices Act. With CEO Andrea Jung on her way out as well, analysts see in the decay of Avon’s upper management glimmers of opportunity.

Avon Initiates External Search For CEO As Jung Steps Down

Avon’s Andrea Jung , who will step down from her role as CEO in 2012 but continue on as Executive Chairman, will aid in the search for a candidate to lead the firm. The Dec. 13 announcement has analysts speculating on how the move will impact the performance of the direct seller.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017818

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel